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Osteogenesis imperfecta (OI) is a heterogeneous group of disorders 
in which skeletal fragility and frequent fractures are the major 
features. The classification and nosology of OI has been through a 
number of revisions reflecting the discovery of new subtypes, initially 
as clinical entities and subsequently defined by their molecular 
aetiology. With increasing knowledge and access to molecular genetic 
testing, it has become evident that there is substantial phenotypic 
overlap with mutations in the same gene. This prompted the 
International Nomenclature Committee for Constitutional Disorders 
of the Skeleton in 2015 to propose a return to a clinical classification 
of five subtypes, as proposed by Van Dijk and Sillence[1] and 
illustrated in Table 1.
In clinical medicine, the most common form of the condition is 
OI type 1 (OI-1). This autosomal dominant (AD) disorder varies in 
severity, but it is usually milder than other types of OI. The other 
well-known condition, OI type 2 (OI-2), causes stillbirth or death 
in the neonate. In this disorder, the fracturing tendency leads to a 
characteristic radiological appearance. A third form of OI, termed 
OI-3, has become the focus of medical and scientific interest. 
This severe condition, which is genetically heterogenous, has the 
descriptive title ‘progressively deforming OI’. Genetic transmission 
of OI-3 can be AD or autosomal recessive (AR), but in the South 
African (SA) population it is most frequently AR.[2] OI-4 is typically 
of moderate severity, whereas OI-5 is characterised by the radiological 
appearance of calcification of interosseous membranes.
A severe AR form of OI-3 is present in a relatively high frequency 
in several indigenous black populations of southern Africa.[3] This 
condition is characterised by numerous fractures, gross deformity 
of tubular bones, spinal malalignment and marked impairment 
of growth. Multiple fractures may be present at birth, but the 
specific radiological appearances in the newborn have not yet been 
documented. Physical handicap is severe and affected children often 
become wheelchair bound. Death before adulthood is frequent. 
Congenital contractures are present in some affected persons; this 
complication has the eponymic designation Bruck syndrome.[4]
The phenotypic manifestations and orthopaedic complications 
in 21 indigenous black African children with AR OI-3 were tabu-
lated[5] and the radiological manifestations in this age group were 
subsequently documented in detail.[6] The high prevalence of OI-3 in 
the black population was emphasised when a minimum population 
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Objective. To delineate the molecular basis for the condition.
Methods. Molecular investigations were performed on 91 affected persons from seven diverse ethnolinguistic groups in this population.
Results. Following polymerase chain reaction amplification and direct cycle sequencing, FKBP10 mutations were identified in 45.1% 
(41/91) OI-3-affected persons. The homozygous FKBP10 c.831dupC frameshift mutation was confirmed in 35 affected individuals in the 
study cohort. Haplotype analysis suggests that this mutation is identical among these OI-3-affected persons by descent, thereby confirming 
that they had a common ancestor. Compound heterozygosity of this founder mutation was observed, in combination with three different 
deleterious FKBP10 mutations, in six additional persons in the cohort. Four of these individuals had the c.831delC mutation.
Conclusion. The burden of the disorder, both in frequency and severity, warrants the establishment of a dedicated service for molecular 
diagnostic confirmation and genetic management of persons and families with OI in southern Africa.
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frequency of 0.6 per 100 000 was established on a basis of 26 
affected persons in 15 families living in the Johannesburg region 
of SA.[3] In contrast, only five affected individuals in this black 
African community had AD OI-1, which is common worldwide. 
An additional 42 children of Shona and Ndebele heritage with 
OI-3 were identified in Zimbabwe, and by the end of 1987, a total 
of 75  affected children in 38 families had been documented.[7] The 
clinical and radiological phenotype was similar in each population, 
and it was proposed that the determinant mutation or mutations may 
be common in the indigenous black communities in southern Africa. 
Whether the geographical and demographic distribution of this 
disorder is the result of selective biological advantage or a founder 
effect, or both, is a matter for speculation.[8]
Although OI-3 is rare, studies in affected persons from different 
parts of the world have revealed causative mutations in several genes: 
CRTAP, P3H1, FKBP10, PPIB, SERPINH1, SERPINF1, BMP1, SP7, 
WNT1, TMEM38B, PLOD2 and CREB3L1.[9] Mutations in FKBP10, 
which encodes FKBP65, have been reported in affected persons 
of Turkish, Mexican-American,[10] German,[11] Saudi Arabian,[12] 
indigenous black South African,[13] Indonesian,[14] Egyptian,[15] 
Italian,[16] Palestinian,[17] Lebanese, Sudanese,[18] Samoan, North 
Ameri can[17,19] and Chinese ancestry.[20] In this context, homozygosity 
for a specific nucleotide insertion, NM_021939.3:c.831dupC, in the 
FKBP10 gene has been demonstrated in OI-3 patient populations 
indigenous to Europe,[10-13] Asia,[21] Africa[13,18] and the Middle East.[12]
Objective
In view of the clinical importance of OI-3 in SA and the fact 
that several different mutations have been shown to underlie this 
condition in other populations, it was imperative that the molecular 
basis of OI-3 in SA should be elucidated.
Methods
Ascertainment
The OI-3 phenotype in SA black children was first recognised as 
an autonomous AR entity by author PB at the Orthopaedic Clinic, 
Chris Hani Baragwanath Hospital, Johannesburg, in 1970. Thereafter, 
numerous affected children of indigenous black African ancestry 
were seen and documented in outreach clinics and institutional 
facilities for the physically handicapped throughout southern Africa. 
From 1972 onwards, data and radiographs were archived in the 
Division of Human Genetics, University of Cape Town (UCT). 
Biological material was obtained from affected children with parental 
permission and was retained for future studies. This investigation 
received clearance from the Faculty of Health Human Research 
Ethics committee at UCT (ref. nos 203/2013 and 192/2014).
Prior to the current project, contact was made with medical 
colleagues in other centres in SA, and they were offered molecular 
genetic screening for mutations in their patients with OI-3 by the 
Division of Human Genetics at UCT. The clinicians caring for affected 
persons with OI-3 and their families submitted blood or saliva 
together with signed consent and permission forms in accordance 
with standard ethical protocols. The clinical diagnosis of OI-3 was 
confirmed by the medical attendant prior to molecular investigation 
in every instance. The molecular findings were transmitted to the 
referring clinicians for the purpose of further medical and genetic 
management. Specimens from a total of 91 persons of indigenous 
black African ancestry were investigated, the majority of whom were 
children. The linguistic subgrouping of these persons reflected the 
geographical distribution of their communities and the whereabouts 
of the referring clinicians and hospital services.
Molecular laboratory investigations
Genomic DNA (100 ng) was amplified by standard polymerase chain 
reaction (PCR) methods for the exon 5 coding region of FKBP10 
in 91 OI-3-affected persons. DNA sequencing was undertaken on 
the ABI3130xl Genetic Analyser using the BigDye v3 terminator 
chemistry (ThermoFisher Scientific, USA) to investigate the region 
of FKBP10 in which the c.831dupC duplication had previously been 
identified.[10,13] Similarly, DNA from two affected persons with a 
heterozygous c.831dupC mutation was PCR amplified and sequenced 
for the remaining coding regions of FKBP10 in an attempt to identify 
both disease-causing mutations. Owing to financial constraints it 
was not possible to sequence FKBP10 in the remaining study cohort.
Two fluorescently labelled multi-allelic markers, rs59064727 and 
rs56965181, were typed by PCR amplification, subsequent capillary 
electrophoresis and fragment analysis on the ABI3130xl Genetic 
Analyser. Allele frequencies were determined for 47 apparently 
healthy persons from the background indigenous black African 
population group. Genotyping was completed for 86 of the 91 OI-3- 
affected persons for whom genomic DNA was available. The resulting 
genotypes were employed to estimate the extent to which OI-3-
affected persons carrying the c.831dupC causative mutation shared an 
85 848-base pair genomic segment, or haplotype, in the vicinity of the 
FKBP10 gene. The statistical software package PHASE version 2.1.1 
(Stephens Lab, University of Chicago, USA),[22] was used to estimate 
haplotype frequencies in the indigenous black African population 
and to infer haplotypes in the OI-3-affected persons. Oligonucleotide 
sequences employed for amplification of multi-allelic markers and 
the FKBP10 coding regions are presented in Table 2.
Results
Molecular pathology
FKBP10 mutations were identified in 45.1% (41/91) of the OI-3-
affected persons. Details of mobility status, z-scores, centiles, age, 
gender, linguistic group and investigation centre are set out in Table 3.
Two frameshift and two nonsense mutations were identified as 
the disease-causing DNA variations in OI-3-affected persons in 
the study cohort. The previously reported frameshift mutation, 
c.831dupC p.(Gly278Argfs95*),[10] was identified, homozygous, in 
38.5% (35/91) of individuals in the study cohort. The c.831dupC 
mutation is predicted to substitute a glycine with an arginine at 
amino acid residue 278 of FKBP65 with the introduction of a 
premature termination codon 95 residues from this substitution 
site. In combination with this common mutation, a novel frameshift 
mutation, c.831delC p.(Gly278Alafs20*), was identified in four 
compound heterozygous OI-3-affected persons from the study cohort 
(Fig. 1). This mutation, unlike the c.831dupC variant, is predicted to 
substitute the glycine 278 residue with an alanine, with subsequent 
introduction of a premature termination codon 20 residues from the 
Table 1. Current OI nomenclature and associated modes of 
inheritance[1]
OI syndrome name Type Inheritance mode
Non-deforming OI with blue sclerae OI-1 AD
Perinatal lethal OI OI-2 AD, AR
Progressively deforming OI OI-3 AD, AR
Moderate OI with normal sclerae OI-4 AD, AR, XL
OI with calcification of the 
interosseous membranes
OI-5 AD
AD = autosomal dominant; AR = autosomal recessive; XL = X linked.
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substitution site. The novel c.343C>T p.(Arg115*) and c.1621C>T 
p.(Gln541*) nonsense mutations are predicted to truncate FKBP65 
by 467 and 41 amino acid residues, respectively.
In a further 50 affected persons, no mutations were identified in 
the FKBP10 regions that were studied.
Haplotype analysis
Haplotypes were constructed to establish whether the high frequency 
of the c.831dupC FKBP10 mutation, present in the OI-3-affected 
population, is the result of a single mutational event in a common 
ancestor, or whether it is the result of a mutational hotspot. Nineteen 
likely haplotypes were inferred with the PHASE version 2.1.1 
soft ware in 86 of the 91 OI-3-affected individuals in this study. 
Every person harbouring the c.831dupC mutation and for whom 
genotyping was completed (n=37) was predicted to share the same 
disease-associated haplotype (3–1) around FKBP10 for rs59064727 
(allele 3) and rs56965181 (allele 1). Persons homozygous for the 
c.831dupC mutation were also homozygous for these alleles. Based 
on the observed allele frequencies for rs59064727 and rs56965181 in 
47 unaffected persons from the background indigenous black African 
population, the frequency of the disease-associated haplotype (3–1) 
was estimated at 4%. The c.831dupC mutation is therefore not present 
on a common haplotype in the background population, suggesting 
that the mutation is identical among the patient population, by 
descent. It is likely that the initial causative mutation occurred in the 
indigenous black African population group before the divergence of 
the linguistic groups that are shown in the OI-3 study cohort (Table 3). 
The c.831delC mutation-associated haplotype in the four compound 
heterozygous individuals with the genotype c.[831dupC];[831delC] 
was 3–7 for rs59064727–rs56965181.
Clinical manifestations
The clinical features in the individuals with OI-3 were generally much 
more severe than those of the common OI-1. There were no obvious 
differences in the phenotypic manifestations in the mutation-positive 
and mutation-negative persons in this investigation. The affected 
persons experienced frequent fractures in early childhood and 
many developed limb deformities. Progressive spinal malalignment 
was frequent. Growth was impaired and reduced stature was usual. 
It is significant that all the patients in whom height or length was 
measured and z-scores calculated fell below the 5th centile (Table 3). 
Three individuals had congenital contractures in the limbs that 
were consistent with a diagnosis of the complication termed Bruck 
syndrome.
The radiological phenotype reflected the sequelae of limb 
fracturing and deformation, together with spinal malalignment. The 
characteristic wormian bones were present in the cranial sutures. 
Elongation of the vertebral pedicles and protrusio acetabulae in the 
pelvis were useful diagnostic indicators.[6]
In all affected individuals the sclerae were white, and a blue 
tinge that was sometimes present in infancy was within normal 
limits. Intellect was normal and there were no relevant visceral 
complications. The 41 homozygotes and compound heterozygotes 
had no clinically evident dentinogenesis imperfecta. In the 50 persons 
in whom no mutation in FKBP10 was detected, dentinogenesis 
imperfecta was variable.
Until recently, the natural history of OI-3 in southern Africa 
was progressive limb and spinal malalignment, with impairment 
of locomotion in early childhood. Walking aids such as sticks and 
crutches often became necessary, spinal compression sometimes 
Table 2. DNA sequences of oligonucleotides employed for PCR amplification of multi-allelic markers and FKBP10 coding and flanking 
intronic regions
Genomic DNA target Sense oligonucleotide (5ʹ - 3ʹ) Antisense oligonucleotide (5ʹ - 3ʹ)
FKBP10 exon1 GTGTCCACTCAGAGTTCTCATC GGGTTAGAGTATTGGGATGC
FKBP10 exon 2 GTGTGTCTGAGGTCACTGTATC GAGCTGCCACTCTTCATACT
FKBP10 exon 3 GCAGAACTCTGAGACCTCCAC AGAGCCGACGTAGGTGTCAT
FKBP10 exon 4 ACTTTGTCCGCTACCACTAC CCTCGTGCAGTATACAACCT
FKBP10 exon 5 CTTACTGGAGGAGCAAGAAG GGAGTAGCTGCAATACAAGG
FKBP10 exon 6 GTCAGGAGGGTCTTGAGGTG GAGTCTGTGTGGCAGGAATC
FKBP10 exon 7 GACCTCAAGTAGCCTCTCCTA GGGACTTACAGAAAGCAGCA
FKBP10 exon 8 CAAGTCACCAGTGGGAGTAAC TCACTTGAACCTGGGAAGTG
FKBP10 exon 9 GCTCCTTAAACATCCCATGC GACTGGTCTCAGGTAGGGAAC
FKBP10 exon 10 CAGCCCTTCCTGAGTTACAG GAACACCAGAGATGTCTCCTC
rs59064727 CCGTCTCTCTAGCTTATCATGG GCCAGGAATATGAGACAAGC
rs56965181 CTGAGATTATGCCACTCCAG GGGTCTCACTATGTTGCCTA
c.[=]
c.[(=)]
A  OI150
c.[=]
c.[831dupC]
B  OI148
c.[831delC]
c.[831dupC]
C  OI99
Fig. 1. Electropherograms produced from direct cycle sequencing for exon 5 
of FKBP10, with inferred allele sequences of three OI-3-affected persons from 
the study cohort. (A) OI150, who has the genotype, c.[=];[(=)], for this region 
of FKBP10. (B) OI148, who was heterozygous for the c.831dupC mutation 
and for whom compound heterozygosity was shown in combination with 
the c.343C>T mutation. (C) An OI-3-affected person (OI99) for whom 
compound heterozygosity was demonstrated in exon 5 of FKBP10, viz. the 
c.[831dupC];[831delC] genotype. The arrow(s) denote the position of the 
duplication/deletion point.
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supervened, and a wheelchair existence was followed by death 
from cardiorespiratory impairment before adulthood. With the 
availability of bisphosphonate therapy, the incidence of complications 
has decreased and long-term prognosis has improved.[23] This has 
changed the age relationships of the phenotype, thereby complicating 
the establishment of genotype-phenotype correlations.
The molecular status of each affected individual is listed in 
Table  3, together with their linguistic and geographical group. 
In clinical medicine, number of fractures, height and the degree 
of restriction of physical mobility are used as an expression of 
severity of the condition in individuals with OI. It is relevant 
that these complications are influenced by numerous exogenous 
factors such as diet, general health and social circumstances. As 
the project was undertaken in several separate academic centres, 
observational variation introduces additional complexity. For all 
these reasons, statistical analysis would have been meaningless and 
was not undertaken. Nevertheless, we consider that the phenotypic 
information that is presented provides a useful indication of the 
clinical severity in the affected persons. It can be concluded that 
there were no obvious discrepancies in the correlation of the 
phenotype with any of the specific mutations recognised in the 
regions of FKBP10 that were investigated.
Table 3. FKBP10 (NM_021939.3) mutations identified in the indigenous black African patient cohort
Genotype Patient ID
No. of 
fractures Mobility z-score Centile
Age 
(years) Sex
Linguistic 
group
Geographical 
region
c.[831dupC];[(831dupC)] OIC25 - - - - 32 M - Bizana
c.[831delC];[831dupC] OIC88 >15 Chairbound –6.7 <0.1 24 F Sesotho Bloemfontein
c.[831delC];[831dupC] OIC90 >10 Chairbound –7.7 <0.1 28 M Sesotho Bloemfontein
c.[831delC];[831dupC] OIC87 >10 Walks with an aid –2.6 0.4 9 F Sesotho Bloemfontein
c.[831delC];[831dupC] OIC99 - - - - 9 M Sesotho Bloemfontein
c.[831dupC];[(831dupC)] OIC85 >5 Walks with an aid –6.3 <0.1 8 F Sesotho Bloemfontein
c.[831dupC];[(831dupC)] OIC68 - - - - 1 M Sesotho Bloemfontein
c.[831dupC];[(831dupC)] OIC153.2 - - - - 19 F Sesotho Bloemfontein
c.[831dupC];[(831dupC)] OIC153.5 - - - - 1 F Sesotho Bloemfontein
c.[831dupC];[(831dupC)] OIC91 10 Chairbound –7.7 <0.1 18 F Xhosa Cape Town
c.[831dupC];[(831dupC)] OIC168 - - - - 11 F Xhosa Cape Town
c.[831dupC];[(831dupC)] OIC120 >10 Chairbound –7.7 <0.1 8 F Zulu Durban
c.[831dupC];[(831dupC)] OIC121 >15 Walks with an aid –7.8 <0.1 10 M Zulu Durban
c.[831dupC];[(831dupC)] OIC122 6 Chairbound –8.3 <0.1 13 F Zulu Durban
c.[831dupC];[(831dupC)] OIC143 >10 Chairbound –10.4 <0.1 13 F Zulu Durban
c.[831dupC];[(831dupC)] OIC82 8 Walks with an aid –7.5 <0.1 17 M Zulu Durban
c.[831dupC];[(831dupC)] OIC67 - - - - 7 F Zulu Durban
c.[831dupC];[343C>T] OIC148 >50 Walks with an aid –9.5 <0.1 12 F Zulu Durban
c.[831dupC];[(831dupC)] OIC147 >10 Walks with an aid –7.7 <0.1 17 M Xhosa Mthatha
c.[831dupC];[(831dupC)] OIC146 >15 Chairbound –5.3 <0.1 14 M Xhosa Mthatha
c.[831dupC];[(831dupC)] OIC144 >10 Chairbound –5.0 <0.1 11 F Xhosa Mthatha
c.[831dupC];[(831dupC)] OIC34 >20 Chairbound –6.6 <0.1 18 F Zulu Pietermaritzburg
c.[831dupC];[(831dupC)] OIC108 8 Chairbound –5.6 <0.1 8 F Zulu Pietermaritzburg
c.[831dupC];[(831dupC)] OIC78 >10 Crawls –6.9 <0.1 7 F Zulu Pietermaritzburg
c.[831dupC];[(831dupC)] OIC77 >10 Walks with an aid –4.5 <0.1 12 M Zulu Pietermaritzburg
c.[831dupC];[(831dupC)] OIC103 >5 Crawls –2.9 0.2 4 F Zulu Pietermaritzburg
c.[831dupC];[(831dupC)] OIC75 5 Walks with an aid –8.8 <0.1 4 F Zulu Pietermaritzburg
c.[831dupC];[(831dupC)] OIC149 >20 Chairbound - - 10 F Zulu Pietermaritzburg
c.[831dupC];[(831dupC)] OIC113 >5 Crawls –2.0 2.6 2 M Sesotho Pretoria
c.[831dupC];[(831dupC)] OIC111 10 Walks with an aid –7.8 <0.1 6 F Sepedi Pretoria
c.[831dupC];[(831dupC)] OIC110 >10 Walks with an aid –7.6 <0.1 10 M Tsonga Pretoria
c.[831dupC];[(831dupC)] OIC114 15 Walks with an aid –6.5 <0.1 8 F Zulu Pretoria
c.[831dupC];[(831dupC)] OIC117 >5 Walks with an aid - - 5 - Sesotho Pretoria
c.[831dupC];[(831dupC)] OIC119 5 Walks with an aid - - 6 M Zulu Pretoria
c.[831dupC];[(831dupC)] OIC154 >5 Crawls - - 3 - Xhosa Pretoria
c.[831dupC];[(831dupC)] OIC155 >20 Chairbound - - 19 - Tswana/
Sesotho
Pretoria
c.[831dupC];[(831dupC)] OIC157 >5 Walks with an aid - - 9 - Tswana/
Sesotho
Pretoria
c.[831dupC];[(831dupC)] OIC158 >5 Walks with an aid - - 5 - Zulu Pretoria
c.[831dupC];[(831dupC)] OIC6 - - - - - F Tsonga Zimbabwe
c.[831dupC];[(831dupC)] OIC8 - - - - 38 F Tsonga Zimbabwe
c.[831dupC];[1621C>T] OIC11 - - - - 47 M Tsonga Zimbabwe
M = male; F = female.
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Discussion
Although the syndromic identity of the SA form of OI-3 was 
recognised more than 40 years ago, until recently the nature of the 
basic defect has remained enigmatic. The observation of a specific 
mutation in the FKBP10 gene in an affected SA boy[13] provided 
the key to elucidation of the molecular pathogenesis, which we 
have now confirmed in a large series of persons with the condition 
in this country. Our molecular investigations were restricted to a 
small region of the FKBP10 gene, and it is relevant that mutations 
were identified in only 45.1% (41/91) of the affected individuals. In 
an additional 50 persons with an identical phenotype in the same 
population group, no mutation was identified in molecular regions 
that were studied, and it seems very probable that further genetic 
heterogeneity remains to be recognised in FKBP10 and possibly 
other genes in this population. The search for the missing mutation 
or mutations is continuing.
The observation of an expansion (c.831dupC) and contraction 
(c.831delC) of the seven cytosine mononucleotide repeat (Fig. 1) in 
OI-3-affected persons from this study cohort supports the notion that 
this region of the FKBP10 gene is prone to mutation.[19] This increased 
mutability may in part contribute to the presence of the c.831dupC 
mutation across geographically diverse population groups worldwide. 
Nevertheless, the evidence suggests that the comparatively high 
incidence of the mutation in southern African populations is the 
result of a common ancestral founder effect.
Two decades ago when relevant biochemical and molecular 
technology became available, involvement of the COL1A1 and 
COL1A2 genes was excluded and it was suggested that in this AR 
form of OI, genes that controlled the processing of type I collagen 
may have been involved.[24] It has now been established that the 
biomolecular mechanism in some forms of AR OI-3 involves 
post-translational modification of collagen. In particular, 3-prolyl 
hydroxylation of fibrillar cartilage is controlled by a complex of the 
proteins encoded by the CRTAP and P3H1 genes. Mutations in these 
genes result in over-modification of collagen.[25-27] In the forms of 
AR OI-3 in which collagen is not over-modified, mutations were 
identified in the FKBP10 and SERPINH1 genes, which chaperone the 
collagen heterotrimer through the endoplasmic reticulum.[10,28]
The association of congenital joint contractures and OI-3 was 
initially documented in five children from families of different 
linguistic groups in the black population of southern Africa 
(Tswana, Pedi and Shona) by Viljoen et al.[29] These authors used 
the eponymous designation Bruck syndrome, based on historical 
precedents.[4] The orthopaedic aspects of additional affected children 
(Venda) were reviewed by Mokete et al.,[30] and DNA was provided for 
a large-scale international investigation undertaken by Kelley et al.[13] 
This study involved molecular screening of material from 47 affected 
individuals with OI in whom the COL1A1, COL1A1, CRTAP and 
P3H1 genes were normal.[13] In four families a total of five affected 
individuals had mutations in the FKBP10 gene. Sequence analysis 
carried out in an affected SA boy from a consanguineous Venda 
family revealed homozygosity for a single nucleotide insertion in 
exon 5, which resulted in a frame shift and premature stop codon 
p.(Gly278Argfs*95). His sister had the typical manifestations of OI-3 
without any contractures, but molecular studies were not undertaken 
in this girl. Homozygosity for the same mutation was also identified 
in an affected daughter from a consanguineous Turkish family.[10] 
A second unrelated indigenous black SA girl with Bruck syndrome 
from a non-consanguineous Tswana family was shown to have 
compound heterozygosity involving this mutation plus another single 
nucleotide insertion in exon 8.[13] These findings by Kelley et al.[13] 
provided impetus for the project that forms the subject of this article.
Conclusion
Now that specific mutations in FKBP10 have been recognised, it 
would be appropriate to establish a dedicated genetic service for 
affected families in southern Africa. This approach could include 
molecular diagnostic confirmation, carrier detection, cascade 
screening, antenatal diagnosis and preimplantation genetic diagnosis. 
In clinical practice in southern Africa, it would be reasonable to 
consider the diagnosis of OI-3 in any person in the indigenous black 
African community with the generic features of OI, especially if the 
manifestations are severe. The white colour of the sclerae and the 
AR mode of transmission in the family would be further diagnostic 
factors in OI-3. In view of the large number of affected children in 
this country and the severity of the condition, this service would 
be cost-effective in terms of both monetary and humanitarian 
perspectives.
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